1.
|
DM ParkinGlobal cancer statistics in the
year 2000Lancet Oncol2533543200111905707
|
2.
|
S NovelloT Le ChevalierChemotherapy for
non-small-cell lung cancer. Part 1. Early-stage
diseaseOncology17357364200312661267
|
3.
|
L De PetrisL CrinòGV ScagliottiTreatment
of advanced non-small cell lung cancerAnn Oncol17ii36ii412006
|
4.
|
C GridelliF PerroneF NelliQuality of life
in lung cancer patientsAnn
Oncol12S21S25200110.1093/annonc/12.suppl_3.S2111804379
|
5.
|
American Society of Clinical
OncologyClinical practice guidelines for the treatment of
unresectable non-small-cell lung cancerJ Clin
Oncol152996301819979256144
|
6.
|
C PerssonU OstlundA Wennman-LarsenY
WengströmP GustavssonHealth-related quality of life in significant
others of patients dying from lung cancerPalliat
Med22239247200810.1177/026921630708533918477718
|
7.
|
G AlbersMA EchteldHC de VetEvaluation of
quality of life measures for use in palliative care: systematic
reviewPalliat Med241734201010.1177/026921630934659319843620
|
8.
|
J BeitzC GneccoR JusticeQuality of life
end points in cancer clinical trials: the U.S. Food and Drug
Administration perspectiveJ Natl Cancer Inst Monogr20791996
|
9.
|
P HarperT PlunketD KhayatQuality trials
and quality of life in non-small cell lung cancerJ Clin
Oncol2130073008200310.1200/JCO.2003.05.07912837809
|
10.
|
K HottaK MatsuoH UeokaMeta-analysis of
randomized clinical trials comparing cisplatin to carboplatin in
patients with advanced non-small-cell lung cancerJ Clin
Oncol2238523859200410.1200/JCO.2004.02.10915326195
|
11.
|
A ArdizzoniL BoniM TiseoCisplatin- versus
carboplatin-based chemotherapy in frst-line treatment of advanced
non-small cell lung cancer: an individual patient data
meta-analysisJ Natl Cancer
Inst99847857200710.1093/jnci/djk19617551145
|
12.
|
J JiangX LiangX ZhouA meta-analysis of
randomized controlled trials comparing carboplatin-based to
cisplatin-based chemotherapy in advanced non-small cell lung
cancerLung
Cancer57348358200710.1016/j.lungcan.2007.03.01417485133
|
13.
|
NK AaronsonS AhmedzaiB BergmanThe European
Organization for Research and Treatment of Cancer QLQ-C30: a
quality of life instrument for use in international clinical trials
in oncologyJ Natl Cancer
Inst85364376199310.1093/jnci/85.5.3658433390
|
14.
|
DF CellaAE BonomiSR LloydReliability and
validity of the Functional Assessment of Cancer Therapy-Lung
(FACT-L) quality of life instrumentLung
Cancer12199220199510.1016/0169-5002(95)00450-F7655830
|
15.
|
K JamesE EisenhauerM ChristianMeasuring
response in solid tumors: unidimensional versus bidimensional
measurementJ Natl Cancer
Inst17523528199910.1093/jnci/91.6.52310088622
|
16.
|
T TangoAn introduction to
meta-analysisMedical Statistical Science Series 4Asakura
bookstoreTokyo991012009
|
17.
|
A WhiteheadMeta-analysis of Controlled
Clinical TrialsJohn Wiley & Sons, LtdChichester2372402002
|
18.
|
NW ScottPM FayersNK AaronsonEORTC QLQ-C30
Reference ValuesJuly2008[updated August 6, 2011]. http://groups.eortc.be/qol/downloads/reference_values_manual2008.pdf.
|
19.
|
DB PetittiMeta-analysis, Decision
Analysis, and Cost-effectiveness AnalysisOxford University
PressOxford, New York1161172010
|
20.
|
P SpectorAn Introduction to S and
S-PlusDuxbury PressBelmont, CA1994
|
21.
|
R RosellU GatzemeierDC BetticherPhase III
randomised trial comparing paclitaxel/carboplatin with
paclitaxel/cisplatin in patients with advanced non-small-cell lung
cancer: a cooperative multinational trialAnn
Oncol1315391549200210.1093/annonc/mdf332
|
22.
|
GV ScagliottiF De MarinisM RinaldiPhase
III randomized trial comparing three platinum-based doublets in
advanced non-small-cell lung cancerJ Clin
Oncol2042854291200210.1200/JCO.2002.02.06812409326
|
23.
|
S DansonMR MiddletonKJ O'ByrnePhase III
trial of gemcitabine and carboplatin versus mitomycin, ifosfamide,
and cisplatin or mitomycin, vinblastine, and cisplatin in patients
with advanced nonsmall cell lung
carcinomaCancer98542553200310.1002/cncr.1153512879472
|
24.
|
A PaccagnellaA FavarettoF OnigaCisplatin
versus carboplatin in combination with mitomycin and vinblastine in
advanced non small cell lung cancer. A multicenter, randomized
phase III trialLung
Cancer438391200410.1016/S0169-5002(03)00280-014698542
|
25.
|
RM RuddNH GowerSG SpiroGemcitabine plus
carboplatin versus mitomycin, ifosfamide, and cisplatin in patients
with stage IIIB or IV non-small-cell lung cancer: a phase III
randomized study of the London Lung Cancer GroupJ Clin
Oncol23142153200510.1200/JCO.2005.03.03715625369
|
26.
|
R BootonP LoriganH AndersonA phase III
trial of docetaxel/carboplatin versus mitomycin
C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin
(MVP) in patients with advanced non-small-cell lung cancer: a
randomised multicentre trial of the British Thoracic Oncology Group
(BTOG1)Ann Oncol17111111192006
|
27.
|
K HottaK MatsuoLong-standing debate on
cisplatin- versus carboplatin-based chemotherapy in the treatment
of advanced non-small cell lung cancerJ Thorac
Oncol296200710.1097/JTO.0b013e31802bb01017410021
|
28.
|
J GoffinC LacchettiPM EllisFirst-line
systemic chemotherapy in the treatment of advanced non-small cell
lung cancer: a systematic reviewJ Thorac
Oncol5260274201010.1097/JTO.0b013e3181c6f03520101151
|
29.
|
S MoritaK KobayashiK EguchiInfluence of
clinical parameters on quality of life during chemotherapy in
patients with advanced non-small cell lung cancer: application of a
general linear modelJpn J Clin
Oncol33470476200310.1093/jjco/hyg08314594941
|
30.
|
G BuccheriF VolaD FerrignoAspects of
quality-of-life in patients with lung-cancer - a 3 observer
evaluation studyInt J Oncol2537544199321573589
|
31.
|
B HolznerRK BodeEA HahnEquating EORTC
QLQ-C30 and FACT-G scores and its use in oncological researchEur J
Cancer4231693177200610.1016/j.ejca.2006.08.01617045472
|
32.
|
MH CullenLJ BillinghamCM
WoodroffeMitomycin, ifosfamide, and cisplatin in unresectable
non-small-cell lung cancer: effects on survival and quality of
lifeJ Clin Oncol1731883194199910506617
|
33.
|
P BonomiK KimD FaircloughComparison of
survival and quality of life in advanced non-small-cell lung cancer
patients treated with two dose levels of paclitaxel combined with
cisplatin versus etoposide with cisplatin: results of an Eastern
Cooperative Oncology Group trialJ Clin Oncol186236312000
|
34.
|
PJ HollenRJ GrallaComparison of
instruments for measuring quality of life in patients with lung
cancerSemin Oncol23314019968610235
|
35.
|
EditorialQuality of life and clinical
trialsLancet34612199510.1016/S0140-6736(95)92643-7
|
36.
|
N ThatcherP HopwoodH AndersonImproving
quality of life in patients with non-small cell lung cancer:
research experience with gemcitabineEur J
Cancer33813199710.1016/S0959-8049(96)00336-X9166093
|